NCT01767376 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age | Biotech Hunter

Enrollment

692

Participants

Timeline

Start Date

January 10, 2013

Primary Completion Date

January 16, 2014

Study Completion Date

January 16, 2014

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612

One dose administered intramuscularly (IM) in the deltoid muscle of the arm.

BIOLOGICAL

Boostrix®

One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).

Trial Locations (15)

45359

GSK Investigational Site, Essen

47574

GSK Investigational Site, Goch

67227

GSK Investigational Site, Frankenthal

77694

GSK Investigational Site, Kehl

78532

GSK Investigational Site, Tuttlingen

95463

GSK Investigational Site, Bindlach

97070

GSK Investigational Site, Würzburg

Unknown

GSK Investigational Site, Santo Domingo, Distrito Nacional

425-707

GSK Investigational Site, Ansan

400 711

GSK Investigational Site, Incheon

700-711

GSK Investigational Site, Incheon

561-712

GSK Investigational Site, Jeonju Jeonbuk

130-702

GSK Investigational Site, Seoul

150-950

GSK Investigational Site, Seoul

158-710

GSK Investigational Site, Seoul